Compositions and methods for CD20 immunotherapy
The present disclosure provides compositions and uses thereof for treating a disease or disorder associated with CD20 expression. Treatments of this disclosure include use of a host cell expressing a fusion protein, such as an anti-CD20 CAR, optionally in combination with a CD20-specific binding molecule, a chemotherapeutic, an inhibitor of an immunosuppression component, or combinations thereof.
1. A fusion protein capable of specifically binding CD20, wherein the fusion protein:
(a) comprises a mature fusion protein, wherein the mature fusion protein comprises the amino acid sequence of any one of SEQ ID NOS.: 35-38 with the tCD19 transduction marker removed;
(b) consists of a mature fusion protein, wherein the mature fusion protein comprises the amino acid sequence of any one of SEQ ID NOS.: 35-38 with the tCD19 transduction marker removed;
(c) comprises the amino acid sequence of any one of SEQ ID NOS.: 26-29; or
(d) consists of the amino acid sequence of any one of SEQ ID NOS.: 26-29.
2. A fusion protein comprising the amino acid sequence of SEQ.ID.NO:26.
3. A composition comprising the fusion protein of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.